A Study of Multiple Doses of ALXN2050 in Healthy Adults

Study identifier:ACH228-002

ClinicalTrials.gov identifier:NCT05047484

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Randomized, Double-Blind, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACH-0145228 in Healthy Participants

Medical condition

Healthy

Phase

Phase 1

Healthy volunteers

Yes

Study drug

ALXN2050, Placebo

Sex

All

Actual Enrollment

45

Study type

Interventional

Age

25 Years - 55 Years

Date

Study Start Date: 07 Jan 2019
Primary Completion Date: 23 Jul 2019
Study Completion Date: 23 Jul 2019

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Basic Science

Verification:

Verified 01 Jul 2024 by Alexion Pharmaceuticals

Sponsors

Alexion Pharmaceuticals

Collaborators

Achillion, a wholly owned subsidiary of Alexion

Inclusion and exclusion criteria